| Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Q Abdool Karim, SS Abdool Karim, JA Frohlich, AC Grobler, C Baxter, ... science 329 (5996), 1168-1174, 2010 | 3057 | 2010 |
| SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ... Nature medicine 27 (4), 622-625, 2021 | 1265 | 2021 |
| Structure and immune recognition of trimeric pre-fusion HIV-1 Env M Pancera, T Zhou, A Druz, IS Georgiev, C Soto, J Gorman, J Huang, ... Nature 514 (7523), 455-461, 2014 | 825 | 2014 |
| Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies … GD Tomaras, NL Yates, P Liu, L Qin, GG Fouda, LL Chavez, AC Decamp, ... Journal of virology 82 (24), 12449-12463, 2008 | 816 | 2008 |
| Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ... Nature 509 (7498), 55-62, 2014 | 780 | 2014 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 716 | 2021 |
| The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, ... Journal of virology 85 (10), 4828-4840, 2011 | 591 | 2011 |
| Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? L Stamatatos, L Morris, DR Burton, JR Mascola Nature medicine 15 (8), 866-870, 2009 | 569 | 2009 |
| Risk factors for coronavirus disease 2019 (COVID-19) death in a population cohort study from the Western Cape Province, South Africa Clinical Infectious Diseases 73 (7), e2005-e2015, 2021 | 543 | 2021 |
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, ... Journal of virology 85 (19), 9998-10009, 2011 | 501 | 2011 |
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1 PL Moore, ET Crooks, L Porter, P Zhu, CS Cayanan, H Grise, P Corcoran, ... Journal of virology 80 (5), 2515-2528, 2006 | 419 | 2006 |
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C JM Binley, EA Lybarger, ET Crooks, MS Seaman, E Gray, KL Davis, ... Journal of virology 82 (23), 11651-11668, 2008 | 418 | 2008 |
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection ES Gray, PL Moore, IA Choge, JM Decker, F Bibollet-Ruche, H Li, ... Journal of virology 81 (12), 6187-6196, 2007 | 416 | 2007 |
| Genetic and Neutralization Properties of Subtype C Human Immunodeficiency Virus Type 1 Molecular env Clones from Acute and Early Heterosexually Acquired … M Li, JF Salazar-Gonzalez, CA Derdeyn, L Morris, C Williamson, ... Journal of virology 80 (23), 11776-11790, 2006 | 410 | 2006 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ... PLoS medicine 2 (4), e112, 2005 | 391 | 2005 |
| Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape PL Moore, ES Gray, CK Wibmer, JN Bhiman, M Nonyane, DJ Sheward, ... Nature medicine 18 (11), 1688-1692, 2012 | 374 | 2012 |
| Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140 A Trkola, TJ Ketas, KA Nagashima, L Zhao, T Cilliers, L Morris, JP Moore, ... Journal of virology 75 (2), 579-588, 2001 | 334 | 2001 |
| Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ... New England Journal of Medicine 384 (11), 1003-1014, 2021 | 320 | 2021 |
| Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines JR Mascola, P D'Souza, P Gilbert, BH Hahn, NL Haigwood, L Morris, ... Journal of virology 79 (16), 10103-10107, 2005 | 300 | 2005 |
| HIV-1 antigen–specific and–nonspecific B cell responses are sensitive to combination antiretroviral therapy L Morris, JM Binley, BA Clas, S Bonhoeffer, TP Astill, R Kost, A Hurley, ... The Journal of experimental medicine 188 (2), 233-245, 1998 | 299 | 1998 |
